A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

137 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-06

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Validation Study on a Prognostic Prediction Model for Respiratory Tract Infections

NCT07109310

Sepsis Acute Respiratory Distress Syndrome Community Acquired Pneumonia +1 more

NOT_YET_RECRUITING

Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures

NCT06916481

Community Acquired or Acquiring Hospital Acquired Pneumonia

RECRUITING

Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study

NCT02557958

Chronic Obstructive Pulmonary Disease

COMPLETED EARLY_PHASE1

Clinical Study of Transcriptome-based Diagnostic Biomarker for Acute Febrile Illness

NCT06552975

Acute Febrile Illness

RECRUITING

Rapid Diagnosis of Severe Respiratory Tract Infectious Diseases and Screening of Biomarkers for Stratified Diagnosis

NCT06533514

Severe Pneumonia Biomarkers

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy.

Enrolled subjects will be followed for 24 months and complete 5 visits to one of the study centers. Blood biomarkers will be collected in addition to other clinical data to determine if these biomarkers can predict disease progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypersensitivity Pneumonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of chronic hypersensitivity pneumonitis
* Age 18 through 85 years.
* Diagnosis of chronic hypersensitivity pneumonitis by HRCT
* Able to understand and sign a written informed consent form.
* Able to understand the importance of adherence to the study protocol and willing to follow all study requirements

Exclusion Criteria

* Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study
* Known explanation for the interstitial lung disease
* Clinical diagnosis of any connective tissue disease
* Listed or expected to receive a lung transplant within 4 months from enrollment
* Pregnant women

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No